Fraiser Kansteiner is a staff writer at Fierce Pharma. He covers a range of topics including pharmaceutical manufacturing, drug delivery, and the impacts of COVID-19, with a focus on medicine and healthcare, pharmaceuticals, and public health. Fraiser's work has been featured in NewsBreak, Biotech, Fierce Pharma, and RealClearHealth.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Fraiser Kansteiner's coverage primarily revolves around the healthcare and pharmaceutical industry, with a focus on regulatory announcements, press releases, and data citations. To effectively reach out to Fraiser, consider providing insights into pharmaceutical industry trends, drug developments or FDA regulations. Sources with access to unpublished data or exclusive information about pivotal events within the healthcare sector may be of particular interest to him.
Since Fraiser does not specify any geographic focus in his articles, it is likely that he covers global pharmaceutical news and would be interested in international perspectives on key issues within the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Fraiser Kansteiner
As Amgen strives to become the industry's top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past weekend with multiple goals in mind.
By: Fraiser Kansteiner
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes, in turn rounding out its oral offering in line with N
By: Fraiser Kansteiner
Even as industry watchers pit the two obesity assets against one another, it’s too early to say whose next-generation incretin stands supreme between Novo Nordisk’s CagriSema and Eli Lilly’s retatr
By: Fraiser Kansteiner
In the air-conditioned haven of the Hilton just downriver from the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, Mike Doustdar spoke with a quiet confidence and a smile a
By: Fraiser Kansteiner
As the United Kingdom juggles industry concerns about the region's waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled in 2024.
By: Kevin Dunleavy, Zoey Becker, Fraiser Kansteiner, Eric Sagonowsky
With the passage of another year in the biz, and another slate of company earnings stacked up against one another, Fierce is finishing the 2025 tally by laying out the annual rankings of the top-paid CEOs among the industry's heavyweights.
By: Fraiser Kansteiner
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its
By: Fraiser Kansteiner
With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary
By: Fraiser Kansteiner
With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies have emerged in recent years on a mission to simplify production for the
Amid efforts in Germany to retool the country’s drug spending, the U.S.
